Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.

Kelly C. Goldsmith,Kimberly Kayser,Susan Groshen,Marc Chioda,Holger Thurm,Joseph Chen,Gerson Peltz,Meaghan Granger,John M. Maris,Katherine K. Matthay,Suzy Ghazarian,Julie R. Park,Esther R. Berko,Araz Marachelian,Yael P. Mosse

Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.

2020

Kelly C. Goldsmith
Kimberly Kayser
Susan Groshen
Marc Chioda
Holger Thurm
Joseph Chen
Gerson Peltz
Meaghan Granger
John M. Maris
Katherine K. Matthay
Suzy Ghazarian
Julie R. Park
Esther R. Berko
Araz Marachelian
Yael P. Mosse

10504Background: Lorlatinib, a potent ALK inhibitor, exerts unprecedented activity against neuroblastoma (NB) derived xenografts harboring common crizotinib-resistant ALK mutations, leading to a fi...

Keywords:

Oncology
Relapsed Neuroblastoma
Internal medicine
Medicine
Refractory
Lorlatinib
Neuroblastoma
in patient
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations